The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 52.00
Bid: 51.00
Ask: 53.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.922%)
Open: 52.00
High: 52.00
Low: 52.00
Prev. Close: 52.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Formation of Cantab Corporate Health Limited

21 Sep 2015 07:00

RNS Number : 5678Z
Cambridge Cognition Holdings PLC
21 September 2015
 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Cambridge Cognition forms Cantab Corporate Health Limited

 

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, announces it has entered into an agreement with Shandwell Ltd ('Shandwell') to launch Cantab Corporate Health Limited ('CCHL') and that CCHL has secured its first contract.

 

CCHL will be dedicated to working with employers and their healthcare providers in delivering sensitive and accurate cognitive assessments in all relevant workplace settings using the proprietary CANTAB™ tests from Cambridge Cognition. The tests are run through iPads and provide reports in minutes, helping identify problems which can then be managed in the workplace. CCHL's business development will be managed by Shandwell, a consultancy business specialising in improving the health and wellbeing of the working population, in return for a minority equity stake in the new entity.

 

CCHL will deliver a new revenue stream to Cambridge Cognition through licensing revenues, royalties and product sales, and it will create a vehicle to access the growing global corporate sector that isn't targeted by the Company's current marketing channels.

 

Occupational health is a very significant near term opportunity. Managing the associated risks of cognitive health is now on the international employer agenda with new initiatives such as The Alzheimer's Society guide for dementia friendly employers. Over 1.3m UK employees now work for employers signed up to the Charter of Employers who are positive about mental health. These trends translate to a UK market, for work related cognitive health assessments, which the Directors estimate to be worth in excess of £26m per annum.

 

Significantly, CCHL has already signed its first contract with a UK provider whose clients include some of the world's leading employers.

 

Dr Steven Powell, Cambridge Cognition's Chief Operating Officer, said: "With an ageing working population, there is an increasing need to manage the associated cognitive health risks. Our technology is being used widely in primary care, research and pharmaceutical development. This new venture with Shandwell, which has an excellent track record of introducing innovation into the corporate health and wellbeing sector, will demonstrate the benefits of our products on an even wider scale."

 

John Picken, Managing Director, of Shandwell said: "There is a growing understanding that cognitive health determines what work we can do and for how long. Closely linked to physical health, it also has a significant impact on performance and productivity. This new venture will give all stakeholders in the health of the working population the opportunity to measure and help manage cognitive health using the latest digital health tools. The tests are culturally neutral, language independent and applicable across all ages and in all occupations from the shop floor to the boardroom. We already have a strong interest for our offer in the UK and considerable global interest."

 

For further information visit www.cantabcorp.com 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

 

 

 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

   

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

 

 

About Shandwell Ltd

Shandwell was established in 2008 by John Picken, ex CEO of Third Party Health Administrator, Medisure. Specialising in improving the health and wellbeing of the working population, it has worked on projects with employers, healthcare providers and government agencies. It has been responsible for developing new and award winning propositions, including managing the key health risks of cancer and obesity. Just prior to forming Cantab Corporate Health with Cambridge Cognition, Shandwell supported a group of some of the world's leading neurologists.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASFMFLAFISEFU
Date   Source Headline
8th Apr 20212:06 pmRNSSecond Price Monitoring Extn
8th Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 202111:05 amRNSSecond Price Monitoring Extn
8th Apr 202111:00 amRNSPrice Monitoring Extension
8th Apr 20217:00 amRNSNew £0.5m contract for cognitive at home testing
30th Mar 20217:00 amRNS£1.3 million contract for a schizophrenia trial
23rd Mar 20217:00 amRNSResults for the year ended 31 December 2020
11th Mar 20217:00 amRNSInvestor Presentation
17th Feb 20216:20 pmRNSHolding(s) in Company
19th Jan 20216:03 pmRNSHolding(s) in Company
19th Jan 202111:06 amRNSSecond Price Monitoring Extn
19th Jan 202111:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSTrading Update, Board Change & Notice of Results
21st Dec 20207:00 amRNSNew digital health contract worth over £700,000
2nd Dec 20201:10 pmRNSHolding(s) in Company
2nd Nov 20202:55 pmRNSGrant of Options
7th Oct 20207:00 amRNSNew £750,000 digital health contract
5th Oct 20207:00 amRNSInvestor Presentation
22nd Sep 20207:00 amRNSInterim Results
21st Sep 20203:13 pmRNSHolding(s) in Company
14th Sep 20207:00 amRNSAppointment of Non-Executive Director
8th Sep 20209:57 amRNSNotice of Results
7th Sep 202012:19 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNS£2m contract for three schizophrenia trials
27th Jul 20201:11 pmRNSResult of AGM and Board Changes
15th Jul 20207:00 amRNSNew virtual study with COVID-19 healthcare workers
3rd Jul 20203:30 pmRNSPosting of Annual Report & Notice of AGM
30th Jun 20209:00 amRNSAnnual Report & Notice of AGM
30th Jun 20207:00 amRNSTrading Update
23rd Jun 20204:18 pmRNSHolding(s) in Company
9th Jun 20207:00 amRNSGrant of Options
5th Jun 20207:00 amRNSCapital Markets Showcase
27th May 20207:00 amRNSOver £1 million of New Contract Wins
6th May 20206:11 pmRNSHolding(s) in Company
6th May 202012:15 pmRNSHolding(s) in Company
5th May 20207:00 amRNSPreliminary Results - Year ended 31 December 2019
29th Apr 20202:19 pmRNSNotice of Results
14th Apr 20207:00 amRNSHolding(s) in Company
14th Apr 20207:00 amRNSHolding(s) in Company
23rd Mar 20204:00 pmRNSDelayed Preliminary Results
19th Mar 20207:00 amRNSAward of Innovative Medicines Initiative grant
17th Mar 20207:00 amRNS£1.37 million of new eCOA contracts
10th Mar 20204:15 pmRNSHolding(s) in Company
10th Mar 20204:15 pmRNSHolding(s) in Company
9th Mar 202012:46 pmRNSResult of General Meeting
19th Feb 20207:01 amRNSFundraising to raise £1.4m & Notice of GM
19th Feb 20207:00 amRNSTrading Update and Notice of Results
10th Jan 20203:54 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSCambridge Cognition expands eCOA and wins contract
31st Oct 20194:17 pmRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.